Mechanistically, AML-derived kynurenine (Kyn) acts as an oncometabolite and 5-hydroxytryptamine receptor 1B (HTR1B), which is a Gi-coupled receptor ligand on osteoblasts, triggering the secretion of serum amyloid A (SAA). This evidence concerns the gene SAA1 and acute myeloid leukemia.